The FDA approved zidesamtinib for previously treated ROS1+ NSCLC based on the ARROS-1 study, which showed a 44% response rate and a 12-month duration of response of 69%. KOLs noted its efficacy, CNS activity, and tolerability, comparing it favorably to other ROS1 TKIs like taletrectinib and repotrectinib. Key discussion points included its potentially better neurotoxicity profile based on cross-trial comparisons and the emerging challenge of sequencing multiple effective agents. Separately, another conversation highlighted the lack of a validated definition for "resectable" stage III NSCLC as a specialty-wide unsolved problem.
“For now to me taletrectinib and zidesamtinib seem to make it into the ROS TKI World Cup final w no perceivable weaknesses as to: ☑️systemic efficacy ☑️CNS protection ☑️safety ☑️activity on res mutations”
— @BalazsHalmosMD · Zidesamtinib · View post ↗📌 Amplified by @KolPulseAI
“Questions remain with CNS disease, G2032R mutation, how to sequence and if possible to combine in the future?”
— @mgonzalezvelMD · Zidesamtinib · View post ↗📌 Amplified by @KolPulseAI
“Problem: there is no validated definition of “resectable” stage III NSCLC. This is largely a case-by-case judgment. This isn’t a PACIFIC flaw, it’s a specialty-wide unsolved problem.”
— @5_utr · Stage III NSCLC · View post ↗A large real-world study found somatic BRCA (sBRCA) alterations are not clinically equivalent to germline (gBRCA) mutations, as patients with sBRCA alterations alone had outcomes on CDK4/6 inhibitors similar to BRCA-wildtype patients. Separately, sequencing in first-line metastatic TNBC after neoadjuvant KEYNOTE-522 is a key topic, with debate around options like IO-based regimens (ASCENT-04), investigational datopotamab deruxtecan, and sacituzumab govitecan.
“sBRCA alterations are not biologically or clinically equivalent to gBRCA mutations. In this large real-world study, shorter CDK4/6i treatment duration was observed only in gBRCA carriers, while patients with sBRCA alterations alone had outcomes similar to BRCA-wildtype patients.”
— @dr_yakupergun · sBRCA vs. gBRCA Outcomes · View post ↗
“mTNBC recurring 14 months post-KN522. CPS 15. Is she an "IO candidate"? If yes, you reach for ASCENT-04. If no, Dato-DXd or SG monotherapy. How are you sequencing the new 1L approvals in the clinic?”
— @DrBarbiOnc · mTNBC Sequencing Debate · View post ↗Bile acid malabsorption (BAM) is a common cause of diarrhea in patients with neuroendocrine tumors (NETs), with studies showing prevalence between 60-90%; it is diagnosable with the BAMRP panel and responsive to bile-acid binding drugs. New real-world research is comparing the effectiveness of first-line NALIRIFOX, mFOLFIRINOX, and gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Other topics include neoadjuvant immunotherapy for dMMR/MSI gastroesophageal adenocarcinoma and treatment de-escalation in MMRd/MSI-H colorectal cancer.
“Bile acid diarrhea (BAD) and bile acid malabsorption (BAM) are common among patients with neuroendocrine tumors and diarrhea.”
— @OncoThor · BAM in NETs · View post ↗
“This new original research compared the real-world effectiveness and recorded safety of first-line NALIRIFOX, mFOLFIRINOX, and gemcitabine plus nab-paclitaxel in treatment-naïve patients with advanced pancreatic ductal adenocarcinoma.”
— @BMJOncology · Pancreatic Cancer Regimens · View post ↗
“Great talk by @ronanhsieh on colorectal cancer at Best of @ASCO in Seattle covering #BREAKWATER, Tx de-escalation in MMRd/MSI-H CRC, role of structured exercise & ctDNA!”
— @PGrivasMDPhD · Colorectal Cancer Topics · View post ↗
“Neoadjuvant immunotherapy followed by surgery versus non-operative management in dMMR/MSI gastroesophageal adenocarcinomas: a case series and review of the literature”
— @Erman_Akkus · Neoadjuvant Immunotherapy · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Quality-of-life data from the LITESPARK-022 trial showed adjuvant pembrolizumab plus the investigational agent belzutifan adds reversible grade 3+ toxicity but does not create a lasting QOL cost for patients with RCC. In advanced RCC, the LITESPARK-011 trial showed little quality-of-life difference between the investigational combination of lenvatinib plus belzutifan versus cabozantinib. Other research highlighted that a whole-genome tumor-informed ctDNA assay detected MRD in 32% of post-nephrectomy patients, and that deferred consolidative nephrectomy after ICI-based therapy resulted in a pathological complete response in ~13% of patients.
“The DFS gain does not come at a lasting quality-of-life cost. Awaiting OS data🩺”
— @katy_beckermann · LITESPARK-022 QOL · View post ↗📌 Amplified by @KolPulseAI
“Results showed little QOL difference in the 2 arms.”
— @tompowles1 · LITESPARK-011 QOL · View post ↗📌 Amplified by @KolPulseAI
“🟢 pCR (0% residual viable tumor) in ~13%”
— @katy_beckermann · Deferred Consolidative Nephrectomy · View post ↗
“After Nephrectomy, 8/25 patients MRD+ (32%) Persistently MRD negative patients with 100% NPV for recurrence”
— @alantanmd · MRD in RCC · View post ↗Data on the investigational FcRH5xCD3 bispecific antibody cevostamab in heavily pretreated relapsed/refractory multiple myeloma (RRMM) showed an overall response rate (ORR) of approximately 44%. In a post-hoc analysis of patients with prior BCMA-directed therapy, median progression-free survival (PFS) was 2.1 months. The regimen featured a fixed duration of 17 cycles.
“⭐️ ORRs looked quite good in the prior BCMA directed therapy cohort, including some deeper responses, BUT median PFS of 2.1 months in prior BCMA Rx on post hoc analysis 😞”
— @ZanwarSaurabh · Cevostamab PFS · View post ↗📌 Amplified by @KolPulseAI
“The best part of this trial was that it was a set duration of treatment !”
— @MyelomaTeacher · Fixed-Duration Therapy · View post ↗📌 Amplified by @KolPulseAI
A publication suggests CD70 overexpression at diagnosis predicts relapse in follicular lymphoma and supports investigation of dual CD19-CD70 CAR-T therapy. Separately, discussions at the LL&M Great Debates conference are addressing the optimal timing for targeted therapy in AML and the role of venetoclax in higher-risk MDS. The potential role of selinexor in myelofibrosis is also being questioned.
“CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma”
— @MostafaFaisal14 · CD70 in Follicular Lymphoma · View post ↗
“Selinexor for myelofibrosis: A drug in search of a disease?”
— @n_gangat · Selinexor in Myelofibrosis · View post ↗
“"When Should Targeted Therapy Enter AML Care?"”
— @madanatyazan · AML Treatment Sequencing · View post ↗